# Summit Says FDA Declined Ivonescimab-Chemotherapy Approval for Some Advanced Lung Cancer Patients

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/57886
Published: 2026-11-15T19:14:57.000Z
Updated: 2026-11-15T19:14:57.000Z
Section: Regulation

> The FDA cited insufficient evidence that the treatment helps patients live longer.

Summit Therapeutics said the U.S. Food and Drug Administration (FDA) declined its application to approve ivonescimab with chemotherapy for certain patients with advanced lung cancer.

Summit said the decision reflected insufficient evidence that the treatment helps patients live longer.